Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 9/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.34 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16699711 | 0.92 | SMN1; SMN2 (0.41) | OPRM1OPRD1OPRK1ALDH1A1POLB | |
| SCHEMBL21867155 | 0.87 | OPRM1 (0.48) | OPRM1OPRD1OPRK1ALDH1A1POLB | |
| SCHEMBL23883496 | 0.87 | ALDH1A1 (0.39) | OPRM1OPRD1OPRK1ALDH1A1POLB | |
| Hydrochloric Acid SCHEMBL20565645 | 0.86 | OPRM1 (0.47) | OPRM1OPRD1OPRK1POLBSLC6A4 | |
| SCHEMBL23883513 | 0.86 | POLB (0.38) | OPRM1OPRD1OPRK1POLBSMN1; SMN2 | |
| SCHEMBL12868735 | 0.81 | ALDH1A1 (0.39) | OPRM1OPRD1OPRK1ALDH1A1POLB | |
| SCHEMBL29067373 | 0.78 | ALOX15 (0.38) | OPRM1OPRD1OPRK1ALDH1A1POLB | |
| SCHEMBL16369822 | 0.78 | POLB (0.36) | OPRM1OPRD1OPRK1ALDH1A1POLB | |
| SCHEMBL29067375 | 0.78 | ALOX15 (0.38) | OPRM1OPRD1OPRK1ALDH1A1POLB | |
| SCHEMBL20564838 | 0.77 | USP2 (0.41) | OPRM1OPRD1OPRK1SMN1; SMN2ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331026-B2 | Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| EP-4536363-A1 | SULFAMIDE DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | Nikang Therapeutics, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| WO-2025072462-A1 | SULFONAMIDE DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| WO-2023240024-A1 | SULFAMIDE DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230303509-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230303509-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230303509-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20200054630-A1 | BENZAMIDES-CONTAINING COMPOUNDS AND THEIR USE IN THE TREATMENT OF DEPRESSION | MINDIMMUNE THERAPEUTICS, INC. | 2020-02-20 | — | — | US | disclosed |
| US-20200054630-A1 | BENZAMIDES-CONTAINING COMPOUNDS AND THEIR USE IN THE TREATMENT OF DEPRESSION | MINDIMMUNE THERAPEUTICS, INC. | 2020-02-20 | — | — | US | disclosed |
| US-10238654-B2 | Benzamides-containing compounds and their use in the treatment of epilepsy | MINDIMMUNE THERAPEUTICS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| WO-2015005901-A1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-15 | — | — | WO | disclosed |
| US-20140107340-A1 | Benzamides | H. LUNDBECK A/S (DK) | 2014-04-17 | — | — | US | disclosed |
| US-20140107340-A1 | Benzamides | H. LUNDBECK A/S (DK) | 2014-04-17 | — | — | US | disclosed |
| US-20140107340-A1 | Benzamides | H. LUNDBECK A/S (DK) | 2014-04-17 | — | — | US | disclosed |
| WO-2014057078-A1 | BENZAMIDES | H. LUNDBECK A/S (DK) | 2014-04-17 | — | — | WO | disclosed |
| WO-2014057078-A1 | BENZAMIDES | H. LUNDBECK A/S (DK) | 2014-04-17 | — | — | WO | disclosed |
| US-20130035326-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-02-07 | — | — | US | disclosed |
| EP-2467137-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2012-06-27 | — | — | EP | disclosed |
| CN-102470127-A | Biaryl compounds and methods of use thereof | AMBIT BIOSCIENCES CORP | 2012-05-23 | — | — | CN | disclosed |
| WO-2011022473-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200054630-A1 | BENZAMIDES-CONTAINING COMPOUNDS AND THEIR USE IN THE TREATMENT OF DEPRESSION | P2RX5, P2RX7, P2RX2 | OPRM1 513/4885OPRD1 342/4885OPRK1 471/4885 |
| US-20140107340-A1 | Benzamides | P2RX7, TRPV1, P2RX5 | OPRM1 363/4885OPRD1 202/4885OPRK1 423/4885 |
| US-20230303509-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | CDK2, CCNK, CCNI | OPRM1 4803/4885OPRD1 4720/4885OPRK1 3724/4885 |
| US-12331026-B2 | Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors | CDK2, CCNK, CCNI | OPRM1 4803/4885OPRD1 4720/4885OPRK1 3724/4885 |
| US-10238654-B2 | Benzamides-containing compounds and their use in the treatment of epilepsy | P2RX5, P2RX7, P2RX6 | OPRM1 1643/4885OPRD1 1577/4885OPRK1 1814/4885 |
| US-20130035326-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | FLT3, CSF3R, CSF1R | OPRM1 3503/4885OPRD1 3782/4885OPRK1 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.